NT5E and neoplasm: Increasing T‐cell infiltration into PDAC might contribute to improving the clinical responses to PD‐1 blockade.[24] Therefore, we conducted a combination therapy of AB680 and anti‐PD‐1, which demonstrated superior synergistic tumor suppression in vivo, consistent with previous studies showing that targeting CD73 could enhance the antitumor activity of immune checkpoint blockade.[25]